Kano S, Kiyota N, Kinoshita I et al (2025) Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer. Jpn J Clin Oncol 55:1131–1140

Article  PubMed  PubMed Central  Google Scholar 

Lee J, Park S, Jung HA et al (2023) A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas. Cancer 129:2966–2974

Article  CAS  PubMed  Google Scholar 

Takahashi H, Tada Y, Saotome T et al (2019) Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol 37:125–134

Article  CAS  PubMed  Google Scholar 

Fushimi C, Tada Y, Takahashi H et al (2018) A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29:979–984

Article  CAS  PubMed  PubMed Central  Google Scholar 

Honma Y, Monden N, Yamazaki K et al (2024) Apalutamide and goserelin for androgen receptor-positive salivary gland carcinoma: a phase II nonrandomized clinical trial, YATAGARASU. Clin Cancer Res 30:3416–3427

Article  CAS  PubMed  Google Scholar 

Locati LD, Cavalieri S, Bergamini C et al (2021) Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: a phase II trial. J Clin Oncol 39:4061–4068

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 21:271–282

Article  CAS  PubMed  Google Scholar 

Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21:531–540

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim HR, Lee SJ, Park S et al (2022) A single-arm, prospective, phase II study of cisplatin plus weekly docetaxel as first-line therapy in patients with metastatic or recurrent salivary gland cancer. Cancer Res Treat 54:719–727

Article  CAS  PubMed  Google Scholar 

Nakano K, Sato Y, Sasaki T et al (2016) Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses. Acta Otolaryngol 136:948–951

Article  CAS  PubMed  Google Scholar 

Okada T, Saotome T, Nagao T et al (2019) Carboplatin and docetaxel in patients with salivary gland carcinoma: a retrospective study. In Vivo 33:843–853

Article  CAS  PubMed  PubMed Central  Google Scholar 

Onaga R, Enokida T, Ito K et al (2023) Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin. Front Oncol 13:1185198

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imamura Y, Tanaka K, Kiyota N et al (2021) Docetaxel plus cisplatin in recurrent and/or metastatic non-squamous-cell head and neck cancer: a multicenter phase II trial. Med Oncol 38:128

Article  CAS  PubMed  Google Scholar 

Barretina J, Caponigro G, Stransky N et al (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603–607

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murai J, Feng Y, Yu GK et al (2016) Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget 7:76534–76550

Article  PubMed  PubMed Central  Google Scholar 

Zoppoli G, Regairaz M, Leo E et al (2012) Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A 109:15030–15035

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng Y, Cai Y, Huang Y et al (2015) High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment. BMC Cancer 15:833

Article  PubMed  PubMed Central  Google Scholar 

Gartrell J, Mellado-Largarde M, Clay MR et al (2021) SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused by DNA-damaging agents. Mol Cancer Ther 20:2151–2165

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kagami T, Yamade M, Suzuki T et al (2020) The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. BMC Cancer 20:1123

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masuda K, Yoshida T, Motoi N et al (2025) Schlafen 11 expression in patients with small cell lung cancer and its association with clinical outcomes. Thorac Cancer 16:e15529

Article  PubMed  PubMed Central  Google Scholar 

Takashima T, Taniyama D, Sakamoto N et al (2021) Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers. Br J Cancer 125:65–77

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taniyama D, Sakamoto N, Takashima T et al (2022) Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy. Cancer Sci 113:784–795

Article  CAS  PubMed  Google Scholar 

Willis SE, Winkler C, Roudier MP et al (2021) Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. Br J Cancer 125:1666–1676

Article  CAS  PubMed  PubMed Central  Google Scholar 

Winkler C, King M, Berthe J et al (2021) SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. JCI Insight 6:e146098

Article  PubMed  PubMed Central  Google Scholar 

Akashi H, Yachida N, Ueda H et al (2024) SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma. Mol Cancer Ther 23:106–116

Article  CAS  PubMed  Google Scholar 

Hamada S, Kano S, Murai J et al (2022) Schlafen family member 11 indicates favorable prognosis of patients with head and neck cancer following platinum-based chemoradiotherapy. Front Oncol 12:978875

Article  CAS  PubMed  Google Scholar 

Kaczorowski M, Ylaya K, Chłopek M et al (2024) Immunohistochemical evaluation of schlafen 11 (SLFN11) expression in cancer in the search of biomarker-informed treatment targets: a study of 127 entities represented by 6658 tumors. Am J Surg Pathol 48:1512–1521

Article  PubMed  Google Scholar 

Conteduca V, Ku SY, Puca L et al (2020) SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy. Mol Cancer Ther 19:1157–1164

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Zhang Z, Fu S et al (2021) Study of clinical predictive value and immune characterization of SLFN11 in clear cell renal cell carcinoma. Int J Gen Med 14:6741–6754

Article  CAS  PubMed